Polymeric liposomal formulation for keratitis

IN606634BActive Publication Date: 2026-10-22COUNCIL OF SCI & IND RES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202111015517
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2021-03-31
Publication Date
2026-10-22
Estimated Expiration
2041-03-31

AI Technical Summary

Technical Problem

Current ocular drug delivery methods for treating fungal keratitis face challenges such as poor ocular bioavailability, rapid drug clearance, and frequent dosing due to the insolubility of lipophilic drugs like amphotericin B, leading to low therapeutic efficacy and potential systemic adverse effects.

Method used

A polymeric liposomal formulation comprising a lipid bilayer, cholesterol, chitosan amino acid conjugates, and antimicrobial drugs, designed to enhance corneal bioavailability and residence time, allowing for sustained release and targeted delivery of antimicrobial agents like amphotericin B, fluconazole, and tobramycin.

Benefits of technology

The formulation achieves improved patient compliance with reduced dosing frequency, increased ocular bioavailability, and prolonged drug retention, maintaining therapeutic levels for extended periods while minimizing systemic toxicity.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A novel composition and method for preparation of corneal adhesive prolong release liposomal eye drop preparation of amphiphilic drugs to improve ocular availability of drug. The present invention relates to novel polymeric liposomal eye drop composition comprising chitosan derivatives, lipids, cholesterol with drugs such as amphotericin B, fluconazole and tobramycin. The prepared polymeric liposomes have enhanced ocular bioavailability, antimicrobial efficacy, corneal residence time. The described formulation resulted in reduction of dose and dosing frequency in the treatment of fungal keratitis. The method and composition of the novel liposomal formulation was applicable for sustain and corneal targeted ocular keratitis.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTIONThe present invention relates to the field of liposomal formulations for drug delivery, in particular liposomal formulations for ocular drug delivery. The present invention particularly relates to polymeric liposomal eye drop composition comprising chitosan amino acid conjugates, lipids, cholesterol and antimicrobial drugs. Liposome's excipients combination is a carrier for enhancing corneal bioavailability of antimicrobial drugs through topical route. The polymeric liposomes have enhanced ocular bioavailability and corneal residence time of drug. The described formulation resulted in reduction of dose and dosing frequency of antimicrobial drugs in the treatment of keratitis. The liposomal formulation is also applicable for sustain release and corneal targeted delivery of drugs. BACKGROUND OF THE INVENTIONFungal keratitis (FK), an inflammation of cornea is mainly caused by pathogenic micro-organisms that invade into corneal ulcer resulting in inflammation and ultimately blindness [A. Leck, et.al., Br J Ophthalmol. 2002 Nov;86(11):1211-5] Of the entire organisms, fungi remain to be most elusive and challenging organism to diagnose and treat [Ansari Z, et.al., Curr Fungal Infect Rep 2013 7, 209-218]. Amphotericin B has a wide spectrum of activity against various fungi including both filamentous and yeast with low incidence of resistance. Topical eye drop instillation is a suitable route of administration for corneal diseases. But the poor ocular bioavailability due to rapid drug clearance by excessive tearing and nasolacrimal drainage limits the treatment of corneal disease. As a result, drug penetration time is too short; hence approximately 5% of the drug is available at the target site. In addition, rapid drainage of the eye drop formulation from the eye surface results in frequent dosing that is inconvenient for the patient. [ WO2012021107A8]Insolubility of lipophilic drug such as amphotericin B in particular impose limitation in for ophthalmic formulation. Currently, amphotericin B (AmB) is available in lyophilized form as Fungizone, Abelcet and AmBisome for intravenous use. As an off-labeled eye drop preparation (0.15% - 0.5%), it is being used as first line therapy for FK administered initially at every 1-2 hr then tapered over 4-6 weeks (Yashpal, et.al. 2014; https: / / www.aao.org / topic-detail / fungal-keratitis-asia-pacific). At present, amphotericin B topical solution (eye drop) for prolong release with reduce dosing frequency isn't available in clinics [Amphotericin B, (Conventional). https: / / www.drugs.com / ppa / amphotericin-b-conventional.html, 2020]. Consequently, the present innovation concerns the area of stable polymeric liposomal preparation for the delivery of topical ophthalmic drugs. In particular, corneal targeted sustained release polymeric liposomes for the treatment of keratitis.Mauro N, et.al, 2019 (Mauro N et.al., J. Pharm. Sci, 2019, 108,2, 960-969) describes the core-shell arginine containing chitosan microparticle loaded sorafenib tosylate to treat retinopathies, able to enhance transcorneal permeation of drugs. The technology has significant challenges in manufacturing and maintaining uniform reproducibility in particle size associated with high cost. In addition, the formulation is projected towards the treatment of posterior segment of eye which limits its therapeutic efficacy towards anterior segment in which FK is prominently observed. There is scarcity of the information regarding ocular bioavailability, efficacy, pharmacokinetic and systemic toxicity which limits to fix the dose and dosing frequency of the micro-particle which is the major problem in the field of eye-drop. Reference is made to US2018280313A1 that describes a nano-structured biocompatible wafer for drug delivery to ocular tissues. The wafer contains a tissue reactive mucoadhesive polymer consisting of xanthan gum, guar gum, chitosan, hyaluronic acid , alginate, xyloglucans, polycarbophil polyacrylic acid, tamarind seed polysaccharide, PEG succinimidyl glutarate, PEG-amine, poly-lysine and a combination thereof for treating an ocular surface disease, disorder, or infection. The formulation includes a drug contained within a plurality of micro-particles formed of a biodegradable polymer and are coated with a tissue reactive compound. The described technology (wafer) is dissimilar in regard to proposed invention (eye-drop). Prolonged residence of wafer (30 days) inside ocular cavity may cause severe irritation, hypersensitivity reactions and probabilistic infections..Reference is made to EP2828332A1 and US8119780B2. They describe the synthesis of chitosan derivatives and the use of chitosan dually derivative with gluconic acid and arginine compounds for gene delivery and chitosan-guanidine / arginine for controlling, microbial biofilm population in a variety of environment respectively. The motive of present invention is different from the proposed invention and doesn't deal in the area of ophthalmology and liposomal eye-drop preparation.CN101011407B describes liposomal amphotericin B eye drop and its preparation comprises of phosphatide, sterol with sugar and buffer. The preparation does not have any corneal targeting properties to improve ocular bioavailability. The current eye infection treatment approaches like, ointment, lens, implants, oral antifungal, and intravenous (IV) liposomal formulations have various untoward effects. Technologies known till date using chitosan derivative have been used for sustain delivery either as microparticle, wafer etc and not as liposome. These particulate solid dosage form such as suspension, microparticle, wafer etc. are often solid dosage form with very slow or poor release and ocular bioavailability. The ocular clearance is increases with increase size form nano to microparticle due to tear flow and shear force of eye lid resulting in low ocular bioavailability. Liposomes are good drug delivery carrier for lipophilic drugs, which are flexible structure and can be formulated as eye drop for easy instillation. Lipophilic drugs such as amphotericin B have higher drug loading in conventional liposomal formulation however cannot withstand the shear force of tear and eye lid resulted in rapid clearance from cornea, resulted in low ocular bioavailability, high dose and dosing frequency to maintain the therapeutic level. Nowadays, off-label application of IV liposomal preparation is very commonly observed in clinics. But high dose and its frequent dosing accrue chances of potential systemic adverse effects (through nasolacrimal passage). Similarly, a pharmaceutical suspension which is used for hydrophobic drug shows high clearance and low ocular bioavailability due to large particle size.In the proposed invention the above-mentioned disadvantages are eliminated and a nano-structured biodegradable polymeric liposomal eye-drop is designed to increase ocular bioavailability and precorneal residence of drugs.. The formulation is composed of corneal targeted polymeric matrix for sustained delivery of lipophilic antifungal drug. The resultant has an advantage of improved patient compliance, reduced dose and dosing frequency.OBJECTS OF THE INVENTION The main objective of the present invention is to develop corneal targeted sustained release eye-drop which increases corneal bioavailability and anti-microbial efficacy of anti-microbial drugs such as amphotericin B, fluconazole, voriconazole and tobramycin.Another objective of the present invention is to develop sustained release eye drop by using conjugated glucosamine (chitosan) amino acid polymer in combination with lipid, cholesterol, cryoprotectant and anti-oxidant in liposomal formulation of antimicrobial drugs.Yet another objective of the present invention is to reduce the dose and dosing frequency by enhancing ocular bioavailability to improve patient compliance.Yet another objective of the present invention is to reduce systemic availability of toxic drug such as amphotericin B following ocular instillation.SUMMARY OF THE INVENTIONThe formulation of the present invention is composed of corneal targeted polymeric matrix for sustained delivery of antimicrobial drug. The resultant has an advantage of improved patient compliance, reduced dose and dosing frequency. The present invention also provides a method for treating fungal keratitis, especially anterior eye disorder, or an ocular surface infection treated by giving polymeric liposomal eye drop. In the drawing and explanation below, the descriptions of one or more embodiments of the invention are set out. Accordingly, the present invention provides a polymeric liposomal formulation for keratitis comprising:(a) at least one lipid bilayer; (b) cholesterol,(c) chitosan amino acid conjugate(d) antimicrobial drug and(e) cryoprotectantwherein, the liposome has a mean diameter of less than 3 μm and the ratio of drug: lipid: cholesterol: chitosan amino acid conjugate is in the range of 1 : 6-10 : 1-3 : 1-8.In an embodiment the chitosan is =75% deacetylated in the chitosan-amino acid conjugate having corneal targeting and bioavailability enhancing properties. In an embodiment of the present invention various liposome, not limiting to formulation disclosed in present invention, can be used as drug carrier depot in the polymeric liposomal formulation. In another embodiment, in the ophthalmic liposomal formulation, the liposomes comprise lipids selected from the group consisting of fatty acyl, glycerolipids, phospholipids, glycerophospholipids, sphingolipids, sterol lipids, preno lipids, saccharolipids, and polyketide lipids. In an embodiment of the present invention the lipid bilayer comprises lipid phosphatidylcholine or a combination of two lipids phosphatidylcholine andN-(Carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (MPEG-2000-DSPE). The lipid bilayer comprises lipid phosphatidylcholine or a combination of two lipids phosphatidylcholine and N-(Carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine Na-salt.In an embodiment of the present invention the amino acid is an anionic, cationic or neutral amino acid. In a preferred embodiment of the present invention the amino acid is selected from the group consisting of aspartic acid, glutamic acid, arginine, histidine, pyroglutamic acid, lysine, isoleucine, methionine, phenyl-alanine, serine, threonine, tyrosine, cysteine and valine. In an embodiment of the present invention the antimicrobial drug is an antifungal or antibacterial drug. In a preferred embodiment of the present invention the antimicrobial drug is selected from the group consisting of amphotericin B, natamycin, tobramycin, fluconazole, voriconazole, gentamycin and moxifloxacin. In an embodiment of the present invention the cryoprotectant is selected from the group consisting of mannitol, sucrose, dextrose and trehalose. In an embodiment of the present invention the formulation is a topical formulation for treatment of pathogenic eye infections. The present invention also provides a process for preparing a polymeric liposomal formulation for keratitis comprising the steps of:a) dissolving the lipids cholesterol in a mixture of chloroform: methanol (2:1 v / v) b) dissolving drug (amphotericin B in acidic methanol (0.05% w / v formic acid) or fluconazole in methanol) and mix in the above lipid mixture. c) preparing a thin film of mixture by evaporating solvent at 50 - 55 °C;d) hydrating the thin film with or without tobramycin aqueous solution under agitation at 55-60 °C to form liposome;e) reducing the size of the hydrated liposome by ultrasonication or extrusion to form a liposome solution;f) mixing the liposome solution with 0.1-1% w / v chitosan-amino acid conjugate solution and cryoprotectant and g) lyophilizing to obtain a polymeric liposomal formulation,wherein, the liposome has a mean diameter of less than 3 μm and the ratio of drug: lipid: cholesterol: chitosan amino acid conjugate is in the range of 1 : 6-10 : 1-3 : 1-8.Another embodiment of the present invention provides a ophthalmic liposomal formulation, wherein polymer can be chitosan, chitosan- amino acid conjugates. The polymeric liposomes are used for preventing pathogenic eye infection. The term pathogen or pathogens is intended to refer to any bacterium, virus, fungus, or any other microorganism that can cause keratitis. In further embodiment of the present invention, with the formulation the dose and dosage regimen is reduced to 2 drops of 0.1% (w / v) at an interval of 4 hr which has negligible systemic availability of drugs following ocular instillation. In an embodiment of the present invention the pharmacokinetic parameter of liposomal formulation has increased AUC (area under curve) and ocular bioavailability whereas, decreased Cl (clearance) and enhanced antifungal efficacy as compare to F10.Another embodiment discusses the formulation that is suitable for veterinary and clinical application. The formulation composition in combination with therapeutic agents can give mucoadhesive and corneal targeted sustain release for maintenance of prolong ocular drug concentration.In another embodiment, the formulation composition of lipid and chitosan-amino acid liposomal complex has high drug loading of antimicrobial drugs such as AmB, fluconazole, tobramycin etc and affinity to cornea. BRIEF DESCRIPTION OF THE DRAWINGSThe invention description below refers to the accompanying drawings, of which:Figure. 1 Illustration of a method for placing of a drug-releasing coated liposome in the eye; Figure. 2 is an NMR spectrum showing conjugation of biodegradable polymer with amino acid i.e., arginineFigure. 3 is an IR spectrum showing conjugation bond between biopolymer and amino acid (chitosan - arginine conjugate).Figure. 4A and 4B shows TEM analysis of uncoated and coated polymeric liposomes F4 respectively.Figure. 5A, 5B,5C and 5D shows a plot of in vitro dialysis release study of amphotericin B obtained after dissolving in DMSO, polymer coated liposome / polymeric liposomes(F4) and F10, FCZ marketed formulation (FMZ) vs. polymeric liposomes F14 respectively.Figure. 6A, 6B, 6C, 6D shows a plot of mucoadhesive test of F4, F7, F8 and F9 respectively.Figure. 7 shows photo images of ocular irritation test of F4 liposomes in rabbit eye after receiving single topical administration at therapeutic dose (0.1 w / v).Figure. 8A, 8B, 8C, 8D, 8E, 8F, and 8G is a plot of tear pharmacokinetic profile of amphotericin B of F4, F7, F8, F9, F5, F12, F10 respectively and Figure 8H is tear pharmacokinetic profile comparison of amphotericin B of F4 and F10. Figure. 9A shows a plot of comparison of tear pharmacokinetic study of fluconazole of F14 and FMZ (Zocon) and 9B shows comparative tear concentration-time profile of tobramycin between Tobastar and F12.Figure. 10 shows a plot of comparison of in vivo precorneal retention pharmacokinetic profile of F4, F7, F8 and F10.Figure. 11A,11B,11C,11D shows a plot of simulated dosage regimen of F4, F7, F8 and F9 respectively in comparison to F10.Figure.12 shows eye images of C. albicans induced keratitis in New Zealand rabbit (disease control).Figure.13 shows diseases progression eye images of fungal keratitis model following F10 treatment. Figure. 14 shows diseases progression eye images of fungal keratitis model following F4 treatment. Figure. 15 shows photo image of corneal histology by H and E staining of (A) normal control, (B) disease control, (C) F10 treated and (D) F4 treated.Figure. 16 shows photo image of retinal histology by H and E staining of (A) normal control (B) disease control (C) F10 treated (D) F4 treated.Figure. 17 shows photo image of eye histology by PAS staining for candida albicans of (A) normal control (B) disease control (C) F10 treated (D) F4 treated.Figure. 18A and 18B shows the photo image of germ test assay for candida albicans and cotton blue staining, respectively.Figure 19 shows the eye image of acute toxicity study of F4 liposomes.ABBREVIATIONSAmB: Amphotericin BFCZ: FluconazoleFK: Fungal keratitisCS: ChitosanMIC: Minimum inhibitory concentrationFMZ: Fluconazole eye drop (Zocon)DETAILED DESCRIPTION OF THE INVENTIONIn the invention, a stable polymeric liposomal formulation is provided for ocular drug delivery to treat microbial keratitis. The formulation includes liposomes containing at least one lipid bilayer that includes a phosphatidylcholine (Phospholipon 90H, Phospholipon 90G), combination of two lipids (phosphatidylcholine and phosphatidylethanolamine -PEG2000). In an embodiment, the liposome is a unilamellar vesicle. The liposomes also contains an antimicrobial drug or a combination of two antimicrobial drugs (antifungal + antibacterial), encapsulated in the liposome. The antimicrobial drugs can be AmB, natamycin, tobramycin, fluconazole, voriconazole, gentamycin, moxifloxacin. The liposomal formulation can also contain synthesized Chitosan - amino acid conj ugate. The amino acids used for chitosan derivatization can be the anionic amino acids, cationic or neutral amino acids. The amino acid can be aspartic acid, glutamic acid, arginine, histidine, pyroglutamic acid, lysine, isoleucine, methionine, phenyl-alanine, serine, threonine, tyrosine, valine.The mole ratio of phosphatidylcholine to cholesterol can be 5:2 to 10:2 w / w or 5:3 to 12:3 w / w. In an embodiment, the ratio for AmB: lipid: cholesterol is 1:7: 3 and 1: 6: 2.5 w / w. The ratio for fluconazole (FCZ): Lipid : Cholesterol is 1:8: 1.9 w / w. The concentration of Chitosan conjugate can be 0.1 to 1% w / v. In the preferred embodiment, chitosan amino-acid concentration used to make stable liposomes are 0.25 and 0.5 % w / v.Also within the scope of the invention is a method for treating an ocular disorder that relies on administering the liposomal formulation described above. The ocular disorder can be ocular keratitis (fungal, bacterial and parasites Keratitis). Preferably, the disorder is fungal keratitis. In an embodiment, the polymeric liposomal formulation is administered topically (as an eye drop).Administering the liposomal formulation described above can cure microbial eye infection. The pharmacokinetic dosage regimen shown effectiveness of formulation when administered at an interval ~ 2 - 10 hr to maintain the drug concentration above MIC ( candida albicans, ca 10231and ATCC90028) for anti-fungal activity. However, the doses regimen may be changed depending on the severity of the disease. Incorporating 10 μl of Candida albicans suspension (1 x 107 cells / ml) in the eye of NZ rabbits resulted in the development of a fungal keratitis (candida albicans) model. On the fifth day of infection, treatment was begun. Initially, eight doses instillation / 24hr of 0.1 % w / v amphotericin B liposomal formulation (F4) was given for first two days depends upon the severity, then six doses for 23 days, results in superior treatment of fungal eye infection as compared to positive control (AmBisome, F10) at the same drug dose and dosing interval. AmBisome (F10) is used as positive control as non-corneal targeted formulation. F10 is as an off-label treatment for eye fungal infection through topical route.From pharmacokinetic study it was observed that the topical polymeric liposomal formulation F4 can slowly release the AmB for approximately 10 hr above the minimum inhibitory concentration (MIC90) of candida albicans after single instillation as compared to positive control (F10) where drug remains for ~ 2 hr above the MIC90 at ocular surface. Thus, improved pharmacokinetic profile of F4 has increased corneal / tear bioavailability reduce required dosing frequency / dose for desire efficacy. On the other hand, polymeric liposomes maintain precorneal FCZ concentration for 4-5 hr above MIC (candida albicans, ATCC90028) as compare to positive control (Zocon eyedrop) which remains 30 minutes above MIC. Whereas, the antibacterial drug, tobramycin (0.3% w / v) remains for 6-7 hr above MIC as compared to positive control (marketed tobramycin ophthalmic solution Tobastar,0.3%). Topical ocular administration is the most promising way for treating of superficial eye diseases (e.g., microbial infections). Despite this, the use of this administration route for treating intraocular pathologies (i.e., retinopathies, microbial infections) is still a challenge for pharmaceutical technologists, because of inefficient retention time on the application and absorption surface as well as low ability of drugs for corneal penetration / retention.Without further elaboration, it is believed that one skilled in the art can, based on the description above, utilize the present invention to its fullest extent. The specific examples below are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.Example 1Synthesis of chitosan-amino acid conjugatesIn order to achieve the above-mentioned aspects i.e., to increase the corneal retention of eye drop at the ocular surface by preparing polymer coated liposomal formulation and in accordance with the purpose of the invention as embodied and describe herein, there is provided a process for the synthesis of compounds as shown in scheme 1. TheseScheme 1Synthesized chitosan-amino acids conjugates were used in polymeric liposomal preparation for ocular drug delivery. The synthesized chitosan-amino acids conjugates were used for coating of liposomes to increase the precorneal retention of antifungal drugs at the corneal surface.Complex formation confirmation by NMR:The formation of chitosan-amino acid conjugate complexe (i - iv) were confirmed by 13C NMR analysis. The formation of chitosan-arginine conjugate was confirmed by the 13C NMR experiment. The effect of binding was clearly observable on chemical shift value of arginine (C7) and the chemical shift value of chitosan (C1). Arginine (C7) shifted up-field from 183.0 ppm to 174.5 ppm due to of conversion of carboxyl group to amide group, whereas chitosan (C1) shifted downfield from 97.6 ppm to 100.6 ppm. This major shift in these key chemical shift values indicated the formation of chitosan-arginine conjugate shown in Figure 2. Similarly, the characteristics signal at ~174.5 ppm (C-7 of amino acids) and signal at ~100.7 ppm (C-1 of chitosan) was present in 13C NMR spectra of other chitosan-amino acid conjugate complexes (ii - iv), which clearly indicated the formation of these chitosan-amino acid conjugate complexes (ii - iv).Complex formation confirmation by FT-IR:The amide bond formation of chitosan - arginine conjugate complex was observed at 3100-3500 cm-1 (N-H stretch). Next guanidine shows characteristic band (N-H stretch) at 1549.8 cm-1 and chitosan was identified by its O-H stretching at 3627.5 cm-1 which clearly indicate the formation of chitosan-arginine conjugate complex shown in Figure 3. Similarly, characteristic signals of amide group (conjugation bond of chitosan and amino acid) were observed in all the chitosan conjugates ((ii - IV) which clearly indicate the formation of these chitosan-amino acid complexes (ii - iv).Example 2Preparation of liposome (A) Preparation of liposomal formulation (F1, F2, F3, F6): A thin film hydration technique was used to formulate AmB - loaded liposomes coated with chitosan / chitosan - arginine conjugate. Briefly, hydrogenated phosphatidylcholine (approx. 85 % stearic acid, approx. 15 % palmitic acid also known as Phospholipon 90H), cholesterol, stearyl amine / stearic acid and AmB were dissolved in a mixture of chloroform: methanol (2:1, v / v), containing 0.05 % formic acid in a dried sterile round bottomed flask (RBF). A thin lipid film was formed on the wall of RBF by completely evaporating organic solvent using rotavapor under reduced pressure at approximately 55 °C, followed by 1 hour of hydration with sterile deionized water at 60 °C. The size of the liposomes was reduced by using a bath sonicator (POWER Sonic 420) for 60 minutes, followed by filtration with a 0. 22μ sterile filter. The chitosan / chitosan-arginine solution (0.25%, w / v) was made by dissolving it in sterile acetic acid deionized water and filtering it through a 0.45μ sterile filter. the chitosan / chitosan-arginine solution was added drop by drop into the liposomal solution under stirring condition. Under the same conditions, the above preparation was mixed for another 30 minutes. The polymeric liposome size was again reduced by both bath and probe (Sonics Vibra Cell) sonication for 20 minutes and 2 minutes ( 20% amplitude, 5 sec pulse in ice bath) respectively. Finally, the polymeric liposomes were mixed with an aqueous sterile cryoprotectant solution. The solution is filled in suitable vial for lyophilization. The preparation of making liposomes was carried out under aseptic condition. The size and zeta potential of polymeric liposomes (F1, F2, F3, F6) ranges between (800nm -2000nm) and (+14 to +24) respectively after reconstitution with sterile water for injection. The individual composition of each formulation is tabulated below:Table 1. Composition of the F1 formulationAmB lyophilized powder to be reconstituted in 6-12 ml of water for injection (WFI)Table 2. Composition of the F2 formulationAmB lyophilized powder to be reconstituted in 6-12 ml of water for injection (WFI)Table 3. Composition of the F3 formulationAmB lyophilized powder to be reconstituted in 6-12 ml of water for injection (WFI)Table 4. Composition of the F6 formulationAmB lyophilized powder to be reconstituted in 6-12 ml of water for injection (WFI)(B) Preparation of liposomal formulation (F4, F7, F8, F9): A thin film hydration technique was used to prepare AmB - loaded polymeric liposomes coated with chitosan - amino acid conjugates [Chitosan-Arginine (F4), chitosan-histidine (F7), chitosan-lysine(F8), chitosan-pyroglutamic acid (F9)]. Briefly, hydrogenated phosphatidylcholine (approx. 85 % stearic acid, approx. 15 % palmitic acid also known as Phospholipon 90H), cholesterol and AmB were dissolved in a mixture of chloroform: methanol (2:1, v / v), containing 0.05 % formic acid in a dried sterile round bottomed flask (RBF). A thin lipid film was formed on the wall of RBF by completely evaporating organic solvent using rotavapor under reduced pressure at approximately 55 °C, followed by 1 hour of hydration with sterile deionized water at 60 °C. The size of the liposomes was reduced by using a bath sonicator (POWER Sonic 420) for 60 minutes, followed by filtration with a 0. 22μ sterile filter. The chitosan amino acid solution (0.5%, w / v) was made by dissolving it in sterile acetic acid deionized water and filtering it through a 0.45μ sterile filter. the chitosan-amino acid solution was added drop by drop into the liposomal solution under stirring condition. Under the same conditions, the above preparation was mixed for another 30 minutes. The polymeric liposome size was again reduced by both bath and probe (Sonics Vibra Cell) sonication for 20 minutes and 2 minutes ( 20% amplitude, 5 sec pulse in ice bath) respectively. Finally, the polymeric liposomes were mixed with an aqueous sterile cryoprotectant solution. The solution is filled in suitable vial for lyophilization. The preparation of making liposomes was carried out under aseptic condition. The size and zeta potential of liposomes (F4, F7, F8, F9) ranges between (800nm -2000nm) and (+30 to +38) respectively after reconstitution with water for injection. The individual composition of each formulation is tabulated below:Table 5. Composition of the F4 formulation AmB lyophilized powder to be reconstituted in 6-12 ml of water for injection (WFI)Table 6. Composition of the F7 formulationAmB lyophilized powder to be reconstituted in 6-12 ml of water for injection (WFI)Table 7. Composition of the F8 formulationAmB lyophilized powder to be reconstituted in 6-12 ml of water for injection (WFI)Table 8. Composition of the F9 formulationAmB lyophilized powder to be reconstituted in 6-12 ml of water for injection (WFI)(C) Preparation of liposomal formulation (F5 and F11): A thin film hydration technique was used to formulate AmB - loaded liposomes coated with chitosan - arginine / lysine conjugate. Briefly, hydrogenated phosphatidylcholine (~98%) from soybean for parental dosage form (also known as Lipoid S PC-3), PE 18:0 / 18:0-PEG2000 [N-(Carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine Na-salt; MPEG-2000-DSPE, also known as Lipoid PE18:0 / 18:0-PEG2000)], cholesterol, and AmB were dissolved in a mixture of chloroform: methanol (2:1, v / v), containing 0.05 % formic acid in a dried sterile round bottomed flask (RBF). A thin lipid film was formed on the wall of RBF by completely evaporating organic solvent using rotavapor under reduced pressure at approximately 52 °C, followed by 1 hour of hydration with sterile deionized water at 60 °C. The size of the liposomes was reduced by using a bath sonicator (POWER Sonic 420) for 60 minutes, followed by filtration with a 0. 22μ sterile filter. The chitosan-arginine / lysine solution (0.5%, w / v) was made by dissolving it in sterile acetic acid deionized water and filtering it through a 0.45μ sterile filter. the chitosan-arginine / lysine solution was added drop by drop into the liposomal solution under stirring condition. Under the same conditions, the above preparation was mixed for another 30 minutes. The polymeric liposome size was again reduced by both bath and probe (Sonics Vibra Cell) sonication for 20 minutes and 2 minutes ( 20% amplitude, 5 sec pulse in ice bath) respectively. Finally, the polymeric liposomes were mixed with an aqueous sterile cryoprotectant solution. The solution is filled in suitable vial for lyophilization. The preparation of making liposomes was carried out under aseptic condition. The size and zeta potential of liposomes F5 and F11 ranges between (400nm - 900 nm) and (+35 to +41) respectively after reconstitution with water for injection. The individual composition of each formulation is tabulated below.Table 9. Composition of F5 formulationAmB lyophilized powder to be reconstituted in 6-12 ml of water for injection (WFI)Table 10. Composition of F11 formulationAmB lyophilized powder to be reconstituted in 6-12 ml of water for injection (WFI)(D) Preparation of liposomal formulation (F12-F13): A thin film hydration technique was used to formulate AmB - loaded liposomes coated with chitosan - amino acid conjugate ( chitosan-arginine / lysine). Briefly, hydrogenated phosphatidylcholine (approx. 85 % stearic acid, approx. 15 % palmitic acid also known as Phospholipon 90H), PE 18:0 / 18:0-PEG2000 (N-(Carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, MPEG-2000-DSPE, Na-salt also known as Lipoid PE18:0 / 18:0-PEG2000), cholesterol, AmB were dissolved in a mixture of chloroform: methanol (2:1, v / v), containing 0.05 % formic acid in a dried sterile round bottomed flask (RBF). A thin lipid film was formed on the wall of RBF by completely evaporating organic solvent using rotavapor under reduced pressure at approximately 52 °C, followed by 1 hour of hydration with sterile deionized water containing tobramycin sulphate at 60°C. The size of the liposomes was reduced by using a bath sonicator (POWER Sonic 420) for 60 minutes, followed by filtration with a 0. 22μ sterile filter. The chitosan-arginine / lysine solution (0.5%, w / v) was made by dissolving it in sterile acetic acid deionized water and filtering it through a 0.45μ sterile filter. The chitosan-arginine / lysine solution was added drop by drop into the liposomal solution under stirring condition. Under the same conditions, the above preparation was mixed for another 30 minutes. The polymeric liposome size was again reduced by both bath and probe (Sonics Vibra Cell) sonication for 20 minutes and 2 minutes ( 20% amplitude, 5 sec pulse in ice bath) respectively. Finally, the polymeric liposomes were mixed with an aqueous sterile cryoprotectant solution. The solution is filled in suitable vial for lyophilization. The preparation of making liposomes was carried out under aseptic condition. The size and zeta potential of liposomes (F14 - F15) ranges between (400nm - 900 nm) and (+32 to +40) respectively after reconstitution with sterile water for injection. The individual composition of each formulation is tabulated below. Table 11. Composition of F12 formulationAmB lyophilized powder to be reconstituted in 6-12 ml of water for injection (WFI)Table 12. Composition of F13 formulationAmB lyophilized powder to be reconstituted in 6-12 ml of water for injection (WFI)Preparation of liposomal formulation (F14): A thin film hydration technique was used to formulate fluconazole loaded liposomes coated with chitosan - amino acid conjugate (chitosan-arginine). Briefly, phosphatidylcholine (Phospholipon 90G, consisting of phosphatidylcholine, lysophosphatidylcholine and tocopherol stabilized with 0.1% ascorbyl palmitate), cholesterol, and fluconazole were dissolved in a mixture of chloroform: methanol (2:1, v / v) in a dried sterile round bottomed flask (RBF). A thin lipid film was formed on the wall of RBF by completely evaporating organic solvent using rotavapor under reduced pressure at approximately 55 °C, followed by 1 hour of hydration with sterile deionized water at 60°C. The size of the liposomes was reduced by using a bath sonicator (POWER Sonic 420) for 30 minutes, followed by filtration with a 0. 22μ sterile filter. The chitosan-arginine solution (0.25%, w / v) was made by dissolving it in sterile acetic acid deionized water and filtering it through a 0.45μ sterile filter. The chitosan-arginine solution was added drop by drop into the liposomal solution under stirring condition. Under the same conditions, the above preparation was mixed for another 30 minutes. The polymeric liposome size was again reduced by bath sonicator for 45 minutes. Finally, the polymeric liposomes were mixed with an aqueous sterile cryoprotectant solution. The solution is filled in suitable vial for lyophilization. The preparation of making liposomes was carried out under aseptic condition. The size and zeta potential of liposomes (F14) ranges between (300 nm - 500nm) and (+30 to +33) respectively after reconstitution with sterile water for injection. The individual composition of each formulation is tabulated below. Table 13. Composition of the F14 formulationFCZ lyophilized powder to be reconstituted in 5 ml of water for injection (WFI).Phospatidylcholine including antioxidants tocopherol and ascorbyl palmitate.The entrapment efficiency of all the formulations discussed above (F1 to F14) ranges between (70 % to 98%). Example 3Lyophilization of liposomes Lyophilization was done for the stability of polymeric liposomes. Freeze drying technique of water replacement was applied for the lyophilization of polymeric liposomes. Dextrose, sucrose, mannitol, mannitol +sucrose, trehalose ratios vary from (2.5 to 20) times to lipid were used as cryoprotectant for lyophilization. The lyophilization process includes deep freezing for 10h, followed by primary drying and secondary drying (at 25 °C) for a span of 24-48 hr , depending on formulation quantity. The condenser temperature was set at -56°C and pressure applied in each step was 0.0002 atm for more than 12 h. Then, freeze-dried liposomes were reconstituted by adding water-for-injection to the original volume of the preparation under gentle agitation for physiochemical characterization. Example 4Characterization of drug loaded polymeric liposomes3) TEM analysis: The morphological characterization of AmB polymeric liposomes was carried out using TEM. A drop of the reconstituted liposomal suspension was placed over the carbon-coated copper grid. The additional sample was withdrawn using filter paper and allowed to stand at 25 ºC for 90 s. A drop of 2% uranyl acetate was applied to stain the liposomes within 60 s. Digital micrograph and soft imaging viewer software (Olympus, Singapore) were used to capture the image and analyze the formulation. TEM investigation confirmed the formation of liposomes and the polymer coating of those liposomes, as shown in Figure 4 A and 4B.1) Drug release study: Drug release studies were performed by membrane dialysis method for AmB and FCZ loaded polymeric liposomes (F4 and F14) by using phosphate buffer saline (pH 7.4) with Tween 80 (0.5% v / v) and (0.1% v / v) respectively as a release medium and the amount of drug released was measured by HPLC-UV. Similarly, the amount of drug release in (F10), and the free AmB was also calculated. The results are shown in Figure. 5A, 5B and 5C. Over a 7 days period, approximately 59% of the AmB was released from the polymeric liposomes while 70% drug was released from F10. The free form of AmB was completely released in 3.5 H. While in case of FCZ marketed eye drop FMZ (Zocon) showed a linear drug released pattern with upto 94% release within 3H and 100% drug release in 4hr while polymeric liposomes containing FCZ shows biphasic and controlled drug release with 75% within 24 H. as shown in Figure 5D.2) Mucoadhesive test: Muco-adhesive properties of cationic polymeric liposomes were examined by changes in zeta-potential value. In mucoadhesive assay, lyophilized liposomal was incubated with aqueous mucin suspension (0.1% w / v) at 37 °C, 100 rpm and the sample were withdrawn at each time point (0.16, 0.5, 1, 2, 4, 6, 8, 10H) up to 10 hr. Zeta potential of each collected sample were measured by zeta-sizer. Change in zeta potential of polymeric liposomes + mucin were compared with blank mucin and liposomes itself without mucin, each measurement was taken trice (n=3). Results of F4, F7, F8 and F9 were shown in Figure 6A,6B,6C and 6D respectively.Example 5In vitro antifungal activity of polymeric liposomesThe in vitro antifungal activity of different formulations of AmB and FCZ loaded polymeric liposomes (F1 - F13) was assayed against C. albicans (ATCC-10231) and Aspergillus (ATCC 204305) strain at a maximal concentration of 25 μg / mL. The susceptibility testing was conducted using RPMI-1640 medium buffered with MOPS, pH 7.0 in 96-well plates using a standard broth micro dilution method according to the Clinical and Laboratory Standard Institute (CLSI). Cell suspensions of C. albicans and Aspergillus were prepared in RPMI 1640 medium and modified to give fnal inoculums concentration of 1.0x103-5.0x103CFU / mL and the plates were incubated at 35°C for 24 hr. The MIC was calculated by both visually and spectrophotometrically at 530 nm using microplate reader. The F10 was used as positive control. Results of antifungal activity of liposomes coated with various chitosan conjugates as well as F10 was shown in Table 14, the activity was expressed as MIC90 representing MIC at which 90% fungal growth has been inhibited. Chitosan-arginine coated polymeric liposomes was better than the F10 while the fungicidal activity of liposomes coated with chitosan- histidine, chitosan - lysine, chitosan-pyroglutamic acid was quite identical (equally potent) to that of F10.Table 14: Antifungal activity of polymeric liposomesEXAMPLE 6In vivo study of polymeric liposomal formulationAnimal studies were performed in accordance with the guidelines of the Animal Ethics Committee "the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), India" ( http: / / cpcsea.nic.in / Auth / index.aspx) ethical guidelines approved by "Institutional Animal Ethics Committee" were also followed.Ocular irritation test at therapeutic dose: The potential ocular irritancy and / or damaging effects of the lyophilized F4 liposomes were evaluated pre-clinically according to a modified Draize test. The test protocol was performed on healthy male New Zealand albino rabbits after a single unilateral application of 40 μL (0.1%, w / v) drug dose of F4 formulation on each rabbit. The contralateral eye was considered as control and left untreated. Ocular tissue examination was performed at the interval of 1, 12, 24, 36, 48, 60 and 72 h after application. The ocular inspection was carried out based on the extent of redness, swelling and the lacrimal discharge produced from the conjunctiva and recorded on a scale of 0-3, 0-4 and 0-6. Furthermore, corneal opacity and iris hyperemia were sorted on a scale of 0-2 and 0-4, respectively. The eye irritation scores for each rabbit were determined by adding the cornea, iris, and conjunctiva irritation scores. The eye irritation score was calculated by dividing the sum of the score for all rabbits by the number of rabbits. Eye discomfort was classified by four practical grades: score 0-3: non-irritating, 4-8: slightly irritating, 9-12: moderately irritating and 13-16: severely irritating / corrosive.The described F4 was found to be non-irritant (score 0-3) when instilled into the rabbit eye shown in Figure 7. There were no signs of redness or swelling observed in the eye. Besides, this experiment may not provide adequate information related to variability in blinking frequency and ocular sensitivity of the rabbit eye.Pharmacokinetic and precorneal retention: The precorneal retention of AmB, tobramycin and FCZ loaded liposomes (F4, F7, F8, F9, F5, F12 and F14), FCZ marketed preparation (FMZ, 0.3% w / v) and AmB marketed preparation (F10, 0.1%, w / v) were evaluated at drug dose of 0.1 % w / v and 0.3% w / v for AmB and FCZ respectively in tear fluid after single instillation in rabbit eye cavity. In each New Zealand rabbits (male, weight: 2.5-3 kg), formulation (40 μL) was instilled into the lower-left cornea-conjunctival sac. The eyelids were closed for 5 sec to prevent drug loss from the cavity. A non-invasive sample collection procedure by fine capillary was adopted for tear collection without touching and irritating ocular surface. Tear samples (10 μL) were collected from each rabbit after dosing at 0.083, 0.25, 0.5, 1, 2, 3, 4, 5, 7, 8, 10 hr. Corneal retention of drug is measured by estimation of drug in tear fluid. Extraction of the calibration, QC and tear samples were performed, further sample analysis was carried out by using LC-MS / MS. Result of pharmacokinetic study of all the liposomal formulations were shown in Figure (8A - 8H) and the pharmacokinetic parameters (area under curve (AUC), half-life (t1 / 2), Cmax, clearance (Cl), volume of distribution (Vd) ) based on tear concentration-time profile were processed using Phoenix WinNonlin software (Certara, New Jersey, USA) shown in Table 15 and 16.In comparison to control (F10), all the polymeric AmB liposomes shows a significant enhancement in AUC, MRT and decrease in clearance (Figure 8A to 8H, Table 15 and 16) indicating the prolong exposure of drug at the precorneal region. Similarly, all the other liposomes F7, F8 and F9 also shows significant increase in pre-corneal retention as compare to control (F10) (Table 15). The relative bioavailability in comparison with control (F10) was shown in Table15. In case of FCZ (Figure 9A), mean resident time (MRT) of polymeric FCZ liposomes was 6 times higher than positive control FMZ at the corneal surface at same dose ocular instillation shown in Table 16. Similarly, F12 has greater bioavailability than commercial preparation Tobastar (Figure 9B). The comparative PK studies of F4, F7, F8 and F10 was shown in Figure 10.Table 15: Pharmacokinetic parameters of liposomal formulation containing AmBTable 16: Pharmacokinetic parameters of liposomal formulation of tobramycin and fluconazole Example 7PK-PD and dosage regimen: PK-PD parameters are used to optimize the dosing regimen to improve the effectiveness and minimize toxicity of antimicrobial agents. Antimicrobials' potency is measured in terms of their MIC. Although the MIC is an excellent measure of antimicrobial agent potency, it lacks time-dependent information. As a result, its correlation with PK parameters is employed to optimize antimicrobial dose to maximize its efficacy. In this regard, following PK-PD indices were used to design dosing regimen and dosing interval to get desire pharmacokinetic profile for efficacy. The results were shown in Figure 11A, 11B, 11C and 11D.EXAMPLE 8In Vivo activity of AmB loaded polymeric liposomesThe efficacy study of AmB loaded polymeric liposomes described above and positive control F10 was carried out in New Zealand rabbits. Animal studies were performed in accordance with ethical guidelines approved by "Institutional Animal Ethics Committee".Inoculum: Candida albicans, ca10231, was maintained in culture on sabouraud's dextrose agar at room temperature and periodically passaged. Prior to each experiment, organisms were transferred onto a fresh plate of sabouraud's dextrose agar and grown to confluence over 3 to 4 days. A sample from the newly inoculated sabouraud's agar was suspended in peptone broth, counted with a hemocytometer and adjusted to a concentration of 1 x 107 cells / ml. The inoculums contained spores. Rabbits were anesthetized with an intramuscular injection of 5 mg / kg xylazine and 15 mg / kg ketamine. Under operating microscope visualization, a syringe with a 30-gauge needle was inserted tangentially into the central corneal stroma to a depth of about one fourth of the corneal thickness and 10 μl of 1 x 107 spores of candida albicans contained in 1mL were injected into the eye of each rabbit.Treatment: There are 4 groups, each group containing three rabbits i) disease control- no eye drop was given to these group of animals. The histological experiment was performed to confirm the disease state of animal.ii) Positive control (F10) and test group (F4) - The dose and dosage regimen in both the groups were same. Treatment of these groups are started at fifth days of infection by eye instillation of 2 drop / dose of 0.1% w / v F10 and F4. Initially, eight dose of eye drop was given at an interval of 2 hr for 2 days and then dose was reduced to 6 doses of eye drop at an interval of 4 hr for next 23 days. At the 30th day animals were enucleated for histological examination. The histological experiment was performed to confirm the disease state of animal.The histological experiment was performed to confirm the disease state of animal.iii) Normal control - Neither inoculum nor drug treatment was given to these group of animals.Germ tube assay- The candida albicans infection in rabbit's eyes was confirmed by germ tube assay. The germ tube test is a diagnostic test in which ocular sample are suspended in animal serum and examined by microscopy for the detection of any germ tubes. It is particularly indicated for colonies of white or cream color on fungal culture, where a positive germ tube test is strongly indicative of candida albicans shown in Figure 18.Result: when the treatment started, all the three groups are in the same diseased condition as shown in Figure 12 -14. In the disease control group, peripheral cornea becoming edematous on 6th day. By days 6-10, the stromal infiltrate had progressed to the surface to produce an epithelial defect with some stromal thinning (Figure. 12), and peripheral vascularization progressing toward the fungal infiltrate. Virtually all rabbits in the untreated group (100%) developed keratitis with anterior chamber pus formation as shown in Figure 12. All these conditions were not appeared in treated group of animals (both in F10 as well as F4).The complications presence was less in F4 treated as compared to F10 treatment. The rabbits were almost cured at the 30th day by the F4 liposomal formulation. While in the F10 treatment group, the animals were still in disease state at the 30th day as shown in Figure 13 and 14. Polymeric liposomal formulation has reduced the time take to cure the infection.Histology Results: Histological results confirm the disease condition of all the three groups i.e., disease control, F10 treated and F4 treated. Results of histological study were shown in Figure 15 to 17. In the disease control group atrophy of corneal epithelium layer, compactness of epithelium and pycnotic nuclei was observed. In the F10 treatment group, moderate corneal epithelium layer thickness not much differentiation of corneal epithelium was observed. While in the F4 formulation the corneal epithelium is as good as normal eye and corneal layer can be differentiated. Retinal section was as good as normal eye in both F10 as well as F4 treated group. Example 9The acute Ocular toxicity study was carried out in accordance with the OECD Guideline 405 method. According to the Test Guideline twelve healthy albino rabbits were used. The animals were assigned in to four groups: control group (1280 μl / day, vehicle control), low dose / day (320 μl), mid dose / day (640 μl) and high dose / day (1280 μl) received correspondingly. The test substance was applied in a single dose in the conjunctival sac of one eye of each animal. The other eye, which remains untreated, serves as a control. Initially, one animal per group used for the effects of any corrosive effect, then two additional animals simultaneously use for confirmation. The eyes were examined at 1, 24, 48, and 72 hours after test substance application. Ocular examination was made by hand slit lamp. The duration of the observation period to evaluate the reversibility of the effects observed up to 21 days. The ocular irritation scores were evaluated in conjunction with the nature and severity of lesions, and their reversibility or lack of reversibility. A careful cage-side examination of each animal was done. At the end of the study, all the animals belonging to treated and control groups were sacrificed and subjected to detail necropsy examination. Assessment of ocular damage / irritation was made according to the numerical evaluation, (from Draize J H (1977) "Dermal and Eye Toxicity Tests" In: Principles and Procedures for Evaluating the Toxicity of Household Substances, National Academy of Sciences, Washington DC p.48 to 49). Any other ocular effects were also noted. The F4 was found to be non- irritant without any adverse effect as shown in Figure 19.

Claims

1. A polymeric liposomal formulation for keratitis comprising of: (a) at least one lipid bilayer, (b) cholesterol, (c) chitosan amino acid conjugate (d) antimicrobial drug and (e) cryoprotectant wherein, the liposome has a mean diameter of less than 3 μm and the ratio of drug: lipid: cholesterol: chitosan amino acid conjugate is in the range of 1 : 6-10 : 1-3 : 1-8.

2. The liposomal formulation as claimed in claim 1, wherein the lipid bilayer comprises lipid phosphatidylcholine or a combination of two lipids phosphatidylcholine and N-(Carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine Na-salt.

3. The liposomal formulation as claimed in claim 1, wherein the chitosan is =75% deacetylated in the chitosan-amino acid conjugate having corneal targeting and bioavailability enhancing properties.

4. The liposomal formulation as claimed in claim 1, wherein the amino acid is an anionic, cationic or neutral amino acid.

5. The liposomal formulation as claimed in claim 1, wherein the amino acid is selected from the group consisting of aspartic acid, glutamic acid, arginine, histidine, pyroglutamic acid, lysine, isoleucine, methionine, phenyl-alanine, serine, threonine, tyrosine, cysteine and valine.

6. The liposomal formulation as claimed in claim 1, wherein the antimicrobial drug is an antifungal or antibacterial drug.

7. The liposomal formulation as claimed in claim 5, wherein the antimicrobial drug is selected from the group consisting of Amphotericin B, natamycin, tobramycin, fluconazole, voriconazole, gentamycin and moxifloxacin.

8. The liposomal formulation as claimed in claim 1, wherein the cryoprotectant is selected from the group consisting of mannitol, sucrose, dextrose and trehalose.

9. The liposomal formulation as claimed in claim 1, wherein the formulation is a topical formulation for preventing pathogenic eye infections.

10. A process for preparing a polymeric liposomal formulation as claimed in claim 1 for keratitis comprising the steps of a) dissolving the, lipids, cholesterol in a mixture of chloroform: methanol(2:1 v / v) b) dissolving drug (amphotericin B in methanol containing 0.05% formic acid in or fluconazole in methanol) and mix in the above lipid mixture. c) preparing a thin film of liposome from the mixture by evaporating at 50 - 55 °C; d) hydrating the thin film with or without tobramycin aqueous solution under agitation at 55-60 °C; e) reducing the size of the hydrated liposome by ultrasonication or extrusion to form a liposome solution; f) mixing the liposome solution with 0.1-1% w / v chitosan-amino acid conjugate solution and cryoprotectant and g) lyophilizing to obtain a dried polymeric liposomal formulation, wherein, the liposome has a mean diameter of less than 3 μm and the ratio of drug: lipid: cholesterol: chitosan amino acid conjugate is in the range of 1 : 6-10 : 1-3 : 1-8.